Maxwell (Max) Skor
Analyst
Morgan Stanley
Equibles does not estimate personal net worth.
About Maxwell (Max) Skor
Maxwell (Max) Skor is recorded as Analyst at Morgan Stanley. Maxwell (Max) Skor has spoken on 3 earnings calls and 1 other investor event across 4 companies, most recently for Ultragenyx Pharmaceutical Inc. on September 17, 2026. Those appearances were for Ultragenyx Pharmaceutical Inc. (RARE), Ascendis Pharma A/S (ASND), Crinetics Pharmaceuticals, Inc. and Cytokinetics Inc (CYTK). The companies whose calls Maxwell (Max) Skor spoke on are classified in the Healthcare sector.
Maxwell (Max) Skor on recent calls
“I was just wondering if you can provide any insights into gross-to-net, particularly in the early stages of the launch. Thanks.”
“Just a quick one on your V-Path durability. I was just wondering if dropouts are still mostly during the titration phase, and if you can comment at all on how reauthorizations are trending.”
“So now that you've outlined the Phase 2-3 design today, were there any key learnings from the Lancet GRACE data or the FDA's RELA-CORLANT PRL that informed how you're thinking about clinically meaningful endpoints or just overall study structure?”
“Could you just confirm whether there are any shared trial sites between Odyssey and Acacia, approximately how many, the percentage overlap, and if so, what potential impact that might have on, let's say, a placebo response or other factors relevant to interpreting Acacia Thank you.”
Affiliation history
-
Morgan Stanley
Analyst
Source not stated
Current
Company network
ASND
Biotechnology · Healthcare
Crinetics Pharmaceuticals, Inc.
Biotechnology · Healthcare
CYTK
Biotechnology · Healthcare
Recent activity
-
-
-
Earnings call
Crinetics Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Crinetics Pharmaceuticals, Inc.
-